166 related articles for article (PubMed ID: 31337525)
1. Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study.
Sakamoto Y; Nishiyama Y; Iwasaki YK; Daida H; Toyoda K; Kitagawa K; Okumura K; Kusano K; Hagiwara N; Fujimoto S; Miyamoto S; Otsuka T; Iguchi Y; Kanamaru T; Yamamoto T; Kaburagi J; Kimura T; Matsumoto T; Kimura K; Shimizu W;
J Cardiol; 2019 Dec; 74(6):539-542. PubMed ID: 31337525
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
Masjuan J; DeFelipe A
Int J Neurosci; 2017 Aug; 127(8):716-725. PubMed ID: 27586690
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
Nogami A; Harada T; Sekiguchi Y; Otani R; Yoshida Y; Yoshida K; Nakano Y; Nuruki N; Nakahara S; Goya M; Origasa H; Kihara Y; Hirao K; Aonuma K;
JAMA Netw Open; 2019 Apr; 2(4):e191994. PubMed ID: 31002317
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
[TBL] [Abstract][Full Text] [Related]
6. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
[TBL] [Abstract][Full Text] [Related]
7. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
Colonna P; von Heymann C; Santamaria A; Matsushita Y; Unverdorben M
Clin Cardiol; 2018 Sep; 41(9):1123-1129. PubMed ID: 30069910
[TBL] [Abstract][Full Text] [Related]
9. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
[TBL] [Abstract][Full Text] [Related]
10. Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain?
Lekuona I; Anguita M; Zamorano JL; Rodríguez JM; Barja de Soroa P; Pérez-Alcántara F
Rev Esp Cardiol (Engl Ed); 2019 May; 72(5):398-406. PubMed ID: 31007166
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Cervantes CE; Merino JL; Barrios V
Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
[TBL] [Abstract][Full Text] [Related]
14. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
[TBL] [Abstract][Full Text] [Related]
15. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
Verma A; Ha ACT; Kirchhof P; Hindricks G; Healey JS; Hill MD; Sharma M; Wyse DG; Champagne J; Essebag V; Wells G; Gupta D; Heidbuchel H; Sanders P; Birnie DH
Am Heart J; 2018 Mar; 197():124-132. PubMed ID: 29447772
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban, a Novel Oral Factor Xa Inhibitor.
Minor C; Tellor KB; Armbruster AL
Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
[TBL] [Abstract][Full Text] [Related]
17. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Geller BJ; Giugliano RP; Braunwald E; Murphy SA; Hanyok JJ; Jin J; Mercuri M; Antman EM; Ruff CT
Am Heart J; 2015 Oct; 170(4):669-74. PubMed ID: 26386790
[TBL] [Abstract][Full Text] [Related]
18. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
19. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
Nishizaki K; Itoh T; Kimura M; Tsushima Y; Shoji Y; Kinjo T; Ishida Y; Sasaki K; Horiuchi D; Sasaki S; Tomita H; Okumura K
J Cardiol; 2017 Jul; 70(1):86-91. PubMed ID: 27816321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
